MEDI0618
MEDI0618 is a proteinase-activated receptor-2 modulator developed by AstraZeneca for migraine,[1] and chronic osteoarthritis[2][3]
References
[edit]- ^ "Late-Breaking Abstracts from the American Headache Society 65th Annual Scientific Meeting June 15-18, 2023, Austin, Texas". Headache: The Journal of Head and Face Pain. 63 (7): 990–1025. July 2023. doi:10.1111/head.14596. PMID 37452471. S2CID 259905192.
- ^ McIntosh, Kathryn A.; Cunningham, Margaret R.; Bushell, Trevor; Plevin, Robin (18 December 2020). "The development of proteinase-activated receptor-2 modulators and the challenges involved". Biochemical Society Transactions. 48 (6): 2525–2537. doi:10.1042/BST20200191. PMC 7752072. PMID 33242065.
- ^ In Kim, Hye; Lee, Gi Baek; Song, Da Eun; Sanjel, Babina; Lee, Wook-Joo; Shim, Won-Sik (15 July 2023). "FSLLRY-NH2, a protease-activated receptor 2 (PAR2) antagonist, activates mas-related G protein-coupled receptor C11 (MrgprC11) to induce scratching behaviors in mice". Life Sciences. 325: 121786. doi:10.1016/j.lfs.2023.121786. ISSN 0024-3205. PMID 37201698. S2CID 258768762.